The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Feb. 01, 2023
Applicant:

Freenome Holdings, Inc., South San Francisco, CA (US);

Inventors:

John St. John, Brisbane, CA (US);

Steven Kothen-Hill, Millbrae, CA (US);

Rui Yang, Burlingame, CA (US);

Adam Drake, Pacifica, CA (US);

Assignee:

Freenome Holdings, Inc., San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/6869 (2018.01); G16B 20/10 (2019.01); G16B 40/20 (2019.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G16B 20/10 (2019.02); G16B 40/20 (2019.02); C12Q 1/6806 (2013.01); C12Q 1/6869 (2013.01); C12Q 2600/154 (2013.01);
Abstract

The present disclosure provides methods and systems for screening or detecting a colorectal cancer or following colorectal disease progression that may be applied to cell-free nucleic acids such as cell-free DNA. The method may use detection of methylation signals within a single sequencing read in identified genomic regions as input features to train a machine learning model and generate a classifier useful for stratifying populations of individuals. The method may comprise extracting DNA from a cell-free sample obtained from a subject, converting the DNA for methylation sequencing, generating sequencing reads, and detecting colon proliferative cell disorder-associated signals in the sequencing information and training a machine learning model to provide a discriminator capable of distinguishing groups in a subject population such as healthy, cancer or distinguishing disease subtype or stage. The method may be used for, e.g., predicting, prognosticating, and/or monitoring response to treatment, tumor load, relapse, or colorectal cancer development.


Find Patent Forward Citations

Loading…